- Home
- EQS vs MRNS Comparison
EQS vs MRNS Comparison
Compare EQS & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- MRNS
- Stock Information
- Founded
- EQS 1991
- MRNS 2003
- Country
- EQS United States
- MRNS United States
- Employees
- EQS N/A
- MRNS N/A
- Industry
- EQS Finance Companies
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- MRNS Health Care
- Exchange
- EQS Nasdaq
- MRNS Nasdaq
- Market Cap
- EQS 18.5M
- MRNS 19.0M
- IPO Year
- EQS N/A
- MRNS 2014
- Fundamental
- Price
- EQS $1.21
- MRNS $0.32
- Analyst Decision
- EQS
- MRNS Buy
- Analyst Count
- EQS 0
- MRNS 12
- Target Price
- EQS N/A
- MRNS $4.28
- AVG Volume (30 Days)
- EQS 3.2K
- MRNS 1.8M
- Earning Date
- EQS 01-01-0001
- MRNS 11-12-2024
- Dividend Yield
- EQS N/A
- MRNS N/A
- EPS Growth
- EQS N/A
- MRNS N/A
- EPS
- EQS N/A
- MRNS N/A
- Revenue
- EQS $1,137,000.00
- MRNS $31,466,000.00
- Revenue This Year
- EQS N/A
- MRNS $15.71
- Revenue Next Year
- EQS N/A
- MRNS $40.57
- P/E Ratio
- EQS N/A
- MRNS N/A
- Revenue Growth
- EQS 1795.00
- MRNS 1.63
- 52 Week Low
- EQS $1.17
- MRNS $0.26
- 52 Week High
- EQS $1.95
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- EQS 41.57
- MRNS 27.41
- Support Level
- EQS $1.18
- MRNS $0.30
- Resistance Level
- EQS $1.25
- MRNS $0.34
- Average True Range (ATR)
- EQS 0.04
- MRNS 0.03
- MACD
- EQS -0.01
- MRNS 0.05
- Stochastic Oscillator
- EQS 16.00
- MRNS 40.24
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.